Research
Viking Therapeutics (VKTX) Stock Analysis & Research
- Latest rating
- Strong Sell
- Latest report
- Oct 29, 2026
- Reports
- 1
- Sector
- Healthcare
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. It develops VK2735, a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, in subcutaneous and oral forms for obesity, and it also…



